BofA Lifts PepGen (PEPG) PT to $3 on Positive DM1 Data Despite Underperform Rating

PepGen Inc. (NASDAQ:PEPG) is one of the hot stocks to buy with huge upside potential. On October 9, BofA raised the firm’s price target on PepGen to $3 from $1 and maintained an Underperform rating on the shares. This sentiment came out as the firm updated its financial model to assign a standalone value to the DM1 program following positive early Phase 1 data that showed splicing correction. The DM1 program refers to the company’s investigational drug, PGN-EDODM1, for treating Myotonic Dystrophy Type 1/D ...